-
Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engager
King, L. A., Veth, M., Iglesias-Guimarais, V., Blijdorp, I., Kloosterman, J., Vis, A. N., Roovers, R. C., Hulsik, D. L., Riedl, T., Adang, A. E. P., Parren, P. W. H. I., van Helden, P. M., de Gruijl, T. D. & van der Vliet, H. J., 20 Dec 2024, In: iScience. 27, 12, 111289.Research output: Contribution to journal › Article* › Academic › peer-review
-
Isolation and expansion of pure and functional γδ T cells
Verkerk, T., Pappot, A. T., Jorritsma, T., King, L. A., Duurland, M. C., Spaapen, R. M. & van Ham, S. M., 15 Feb 2024, In: Frontiers in immunology. 15, 15 p., 1336870.Research output: Contribution to journal › Article* › Academic › peer-review
-
Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion
King, L. A., de Jong, M., Veth, M., Lutje Hulsik, D., Yousefi, P., Iglesias-Guimarais, V., van Helden, P. M., de Gruijl, T. D. & van der Vliet, H. J., 2024, In: Frontiers in oncology. 14, p. 1474007 1474007.Research output: Contribution to journal › Article* › Academic › peer-review
- All publications
